Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirbanibulin for Actinic Cheilitis (Cheilitis Trial)
2022-502807-31-00Phase 2Completed
- Sponsor
- Technische Universität Dresden
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tirbanibulin in actinic cheilitis (AC), sponsored by Technische Universität Dresden. Primary endpoint: Complete recovery rate (healing) of Actinic Cheilitis at week 8. Started Jul 2023; status: completed.
02
Drugs
tirbanibulin
03
Conditions
actinic cheilitis (AC)
Beyond the preview
Go deeper on 2022-502807-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502807-31-00.